HOUSTON - Kiromic BioPharma, Inc. (OTCQB: KRBP) (Kiromic or the Company) Provides Update on Part 1 of the Deltacel-01 Trial’
Kiromic BioPharma, Inc. a leading biotechnology company, has announced promising interim results from Part 1 of its ongoing Deltacel-01 Phase 1 clinical trial. The trial is aimed at evaluating the efficacy and safety of Deltacel (KB-GDT-01), an allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have not responded to standard treatments.
The Deltacel-01 trial represents a pioneering approach in the use of GDT therapy, which leverages the natural immunological properties of gamma delta T-cells to combat cancer. These cells are known for their potential to recognize and eliminate malignant cells without the need for genetic modification, making them a versatile option for cancer therapy.
As of the latest reports, interim results have been gathered from five patients who were assessed for Progression-Free Survival (PFS) and overall safety. Though detailed data on the specific outcomes for each of these patients have not been disclosed, the company has been able to provide a snapshot of encouraging clinical activity.
Significant Tumor Reduction Observed in the First Enrolled Patient’
In particular, Kiromic BioPharma highlighted the eight-month follow-up results of the first patient enrolled in the trial. This patient exhibited a remarkable 20% reduction in tumor size, as confirmed by imaging scans taken eight months post-treatment. This reduction is significant, signifying that Deltacel (KB-GDT-01) could potentially offer a viable therapeutic option for patients with advanced NSCLC who have exhausted other treatment avenues.
The favorable outcome with this initial patient provides a glimmer of hope for the use of GDT therapies in combating hard-to-treat cancers. The Deltacel-01 trial aims to compile more comprehensive data as it proceeds, which would establish the systemic impacts and longevity of the therapeutic benefits observed thus far.
Continuing the Path of Innovation in Cancer Therapy’
Kent Watson, Chief Scientific Officer at Kiromic BioPharma, commented on the interim results, stating, These early findings are promising and signify an encouraging step forward in our pursuit of innovative cancer treatments. The observed tumor reduction is particularly noteworthy and aligns with the potential we envisioned when developing Deltacel.
The insights gained from Part 1 of the Deltacel-01 clinical trial will inform further phases of research and address crucial aspects of safety, dosage, and long-term efficacy. As research and follow-up continue, Kiromic is committed to refining its therapeutic approach to maximize patient outcomes.
Outlook and Future Prospects’
With the clinical landscape of NSCLC requiring novel interventions, the emergence of allogeneic, off-the-shelf therapies like Deltacel represents a beacon of progress. Kiromic BioPharma’s dedication to fostering innovative cancer treatments underscores the broader of offering renewed hope to patients with challenging prognoses.
For patients and stakeholders alike, the interim results from the Deltacel-01 trial mark a noteworthy advancement, potentially laying the groundwork for future breakthroughs in cancer immunotherapy.
Comments